Certolizumab pegol Brand Name– Cimzia
What is Certolizumab pegol
Certolizumab pegol is a TNF-alpha blocker (TNF-blocker) conjugated to polyethylene glycol for subcutaneous use. As with other TNF-blockers, the drug is useful in treating many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis.
In adults with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) the drug improves clinical signs and symptoms, inhibits the radiographic progression of structural joint damage, and improves physical function; in adults with ankylosing spondylitis (AS), the drug improves clinical signs and symptoms of active disease, which can improve quality of life. For adult RA, PsA or AS, certolizumab may be used as monotherapy; the drug may also be used with other disease-modifying antirheumatic drugs (DMARDs).
The ideal combination of therapy for individual patients with inflammatory arthritis conditions is determined by treat to target strategies and severity of disease.
For PsA, TNF-blockers are considered a first-line treatment, even in treatment-naive patients.
Certolizumab pegol is beneficial in adults with moderate to severe plaque psoriasis; TNF-blockers may be used as first-line systemic treatments alone or in combination with other therapies.
In moderately to severely active Crohn’s disease, certolizumab pegol reduces signs and symptoms of the disease and maintains clinical response.
As with other TNF blockers, certolizumab pegol labeling carries a boxed warning regarding the risk for serious infections, including tuberculosis, and the potential risk of malignancy.
Indications
- ankylosing spondylitis
- Crohn’s disease
- non-radiographic axial spondyloarthritis
- psoriasis
- psoriatic arthritis
- rheumatoid arthritis
For the treatment of Crohn’s disease
to reduce signs and symptoms and to maintain clinical response in patients with moderately to severely active Crohn’s disease who have an inadequate response to conventional therapy
Side Effects
- anaphylactoid reactions
- anemia
- angina
- angioedema
- antibody formation
- anxiety
- aplastic anemia
- arthralgia
- atrial fibrillation
- back pain
- bleeding
- cough
- cystitis
- dizziness
- dyspnea
- edema
- elevated hepatic enzymes
- erythema
- erythema multiforme
- fatigue
- fever
- Guillain-Barre syndrome
- headache
- heart failure
- hepatitis
- hypertension
- hypotension
- infection
- infection
- injection site reaction
- laryngitis
- leukemia
- leukopenia
- lichen planus-like eruption
- lupus-like symptoms
- lymphadenopathy
- lymphoma
- malaise
- myocardial infarction
- new primary malignancy
- optic neuritis
- pancytopenia
- pericardial effusion
- pericarditis
- peripheral neuropathy
- pharyngitis
- phlebitis
- psoriasis
- rash
- renal failure (unspecified)
- retinal hemorrhage
- seizures
- serum sickness
- sinusitis
- skin cancer
- skin discoloration
- Stevens-Johnson syndrome
- stroke
- suicidal ideation
- syncope
- thrombocytopenia
- toxic epidermal necrolysis
- urticaria
- uveitis
- vasculitis
Monitoring Parameters
- antinuclear antibody (ANA) titer
- CBC
- hepatitis B serology
- tuberculin skin test
Contraindications
- acquired immunodeficiency syndrome (AIDS)
- aplastic anemia
- autoimmune disease
- bone marrow suppression
- breast-feeding
- children
- corticosteroid therapy
- diabetes mellitus
- fungal infection
- geriatric
- Guillain-Barre syndrome
- heart failure
- hepatitis B exacerbation
- history of angioedema
- human anti-chimeric antibody (HACA)
- immunosuppression
- infants
- infection
- influenza
- laboratory test interference
- latex hypersensitivity
- leukopenia
- lymphoma
- multiple sclerosis
- mycobacterial infection
- neonates
- neoplastic disease
- neurological disease
- new primary malignancy
- pregnancy
- sepsis
- skin cancer
- surgery
- thrombocytopenia
- tuberculosis
- vaccination
- viral infection
Interactions
- Abatacept
- Adalimumab
- Anakinra
- Antithymocyte Globulin
- Azathioprine
- Bacillus Calmette-Guerin Vaccine, BCG
- Baricitinib
- Basiliximab
- Belimumab
- Canakinumab
- Cyclophosphamide
- Cyclosporine
- Dexamethasone
- Efalizumab
- Etanercept
- Golimumab
- Infliximab
- Influenza Virus Vaccine
- Intranasal Influenza Vaccine
- Live Vaccines
- Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
- Measles/Mumps/Rubella Vaccines, MMR
- Methotrexate
- Methylprednisolone
- Muromonab-CD3
- Natalizumab
- Prednisolone
- Prednisone
- Rilonacept
- Rituximab
- Rituximab; Hyaluronidase
- Rotavirus Vaccine
- Rubella Virus Vaccine Live
- Sarilumab
- Smallpox and Monkeypox Vaccine, Live, Nonreplicating
- Smallpox Vaccine, Vaccinia Vaccine
- Tocilizumab
- Tofacitinib
- Typhoid Vaccine
- Upadacitinib
- Varicella-Zoster Virus Vaccine, Live
- Vedolizumab
- Yellow Fever Vaccine, Live
